A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

So far, Altmetric has seen 8 X posts from 5 X users, with an upper bound of 6,966 followers.

Provocative results!

RT @EpicentRx: From Parkinson’s, Alzheimer’s and multiple sclerosis (MS) to glioblastoma (GBM), RRx-001 has consistently demonstrated evide…

RT @EpicentRx: #NEWS: RRx-001 not only crosses the blood-brain barrier but is the only NLRP3 inhibitor that has been evaluated clinically i…

RT @FrontOncology: New research: A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide follow…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.